Met kinase inhibitors

Details Met kinase inhibitors Met kinase inhibitors

2006-09-28

2009-06-16

Berch, Mark L (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C544S298000, C544S322000, C544S333000, C544S317000, C544S328000, C544S327000, C544S122000, C544S324000, C544S091000, C544S131000, C546S113000, C546S262000, C546S014000, C546S316000, C546S323000, C546S261000, C546S268100, C546S291000, C423S325000, C556S400000

Reexamination Certificate

active

07547782

ABSTRACT:
The present invention is directed to compounds having the formula I or II:including salts thereof, and methods for using them for the treatment of cancer.

REFERENCES:
patent: 6869952 (2005-03-01), Bhide et al.
patent: 6969717 (2005-11-01), Bhide et al.
patent: 0151962 (1985-08-01), None
patent: 0119774 (1987-06-01), None
patent: 0152910 (1989-07-01), None
patent: WO91/08211 (1990-12-01), None
patent: WO95/00511 (1995-01-01), None
patent: WO97/49704 (1997-12-01), None
patent: WO99/58533 (1999-11-01), None
patent: WO00/41505 (2000-07-01), None
patent: WO00/71129 (2000-11-01), None
patent: WO01/57040 (2001-08-01), None
patent: WO01/94353 (2001-12-01), None
patent: WO02/40486 (2002-05-01), None
patent: WO02/055501 (2002-07-01), None
patent: WO02/081728 (2002-10-01), None
patent: WO03/000194 (2003-01-01), None
patent: WO03/040102 (2003-05-01), None
patent: WO03/042172 (2003-05-01), None
patent: WO03/082208 (2003-10-01), None
patent: WO03/091229 (2003-11-01), None
patent: WO2004/048386 (2004-06-01), None
patent: WO2004/054514 (2004-07-01), None
patent: WO2004/106305 (2004-12-01), None
patent: WO2005/021554 (2005-03-01), None
patent: WO2005/044793 (2005-05-01), None
Lutterback, et al., Cancer Res. 2007; 67 (5) Mar. 1, 2007.
Park, et al., Breast Can. Res., vol. 7, Suppl. 1, VI Madrid Breast Cancer Conf., p. S22, #P12.
Stenina, et al., Nature Med., vol. 11, No. 4, Apr. 2005.
Amemiya, et al., Oncology 2002;63:286-296 (Abstract).
Mazzone, et al., The FASEB Journal vol. 20, Aug. 2006, 1611-1621.
Park, et al., Breast Can. Res., vol. 7, Suppl. 1, VI Madrid Breast Can. Cionf. S22, #P12, Jun. 2005.
Bardelli et al.,Concomitant activation of pathways downstream of Grb2 and Pl3-kinase is required for MET-mediated metastasis, Oncogene (1999) 18, 1139-1146.
Barker et al.,Thienopryrdines. Part 7. Some Electrophilic Substitution Reactions of Thieno [2,3-b] pyridine isosteres of 4-oxygenaed and 2,4-dioxygenated Quinolines, J. Chem. Research (S) 1986, pp. 122-123.
Battesti et al.,Recherches sur des pyrazolo-pyridazines et pyrimido-pyridazines. V.-Action d'hydrazines sur un derive du furanne, Bull. Soc. Chim. Fr., 1975, 2185-2188.
Bottaro et al.,Identification of the Hepatocyte Growth Factor Receptor as the c-met Proto-Oncogene Product, Science 251: 802-4, 1991.
Bussolino et al.,Hepatocyte Growth Factor is a Potent Antiogenic Factor Which Stimulates Endothelial Cell Motility and Growth, J. Cell Biology, vol. 119, No. 3, Nov. 1992 629-641.
Camp et al.,Met Expression is Associated with Poor Outcome in Patients with Axillary Lymph Node Negative Breast Carcinoma, Cancer 86, 2259-2265 (1999).
Chan et al.,Copper promoted C-N and C-O bond cross-coupling with phenyl and pyridylboronates, Tetrahedron Lett 44 (2003) 3863-3865.
Christensen et al.,A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo, Cancer Research 63, 7345-7355, Nov. 1, 2003.
Cooper et al.,Amplification and overexpression of the met gene in spontaneously transformed NIH3T3 mouse fibroblasts, EMBO Journal vol. 5, No. 10, pp. 2623-2628 (1986).
DiRenzo et al.,Overexpression and Amplification of the Met/HGF Receptor Gene during the Progression of Colorectal Cancer, Clinical Cancer Research vol. 1, 147-154, Feb. 1995.
Dorn et al.,Unambiguous Synthesis of 4,7 Dihydro-4-exo-1H-pyrazolo [3,4-b] pyridine, J. Prakt. Chem (1982) 324, 557-562.
Furge et al.,Met receptor tyrosine kinase: enhanced signaling through adapter proteins, Oncogene (2000) 19, 5582-5589.
Gual et al.,Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis, Oncogene (2000) 19, 1509-1518.
Galeeva, R.N. et al., Khim. Farm. Zh. 1998, 32, 31.
Gelin, Suzanne,Synthesis and Reactions of Some 5-Hydrozypyridazinium Hydroxide Inner Salts from 3(2H)-Furanones, J. Org. Chem. vol. 44, No. 17, 1979, pp. 3053-3057.
Greene et al.,Protective Groups in Organic Synthesis, Wiley, NY, (1991).
Hagmann et al.,Substituted 2-Aminopyridines as Inhibitors of Nitric Oxide Synthases, Bioorganic & Medicinal Chem. Lett. 10 (2000) 1975-1978.
Hennequin et al.,Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors, J. Med. Chem. 1999, 42, 5369-5389.
Howe, Robert K.,Reaction of Ethyl β-Aminocrotonate with Trichloromethanesulfenyl Chloride, J. Org. Chem., vol. 42, No. 20, 1977.
Hunt et al.,Discovery of the Pyrrolo[2,1-f)[1,2,4] triazine Nucleus as a New Kinase Inhibitor Template, J. Med. Chem. 2004, 47, pp. 4054-4059.
Ishiyama et al.,Palladium (0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters, J. Org. Chem. (1995), 60, 7508-7510.
Itoh et al.,Studies on the Chemical Synthesis of Potential Antimetabolites, J. Heterocyclic Chem (1982) 19, 513-517.
Jiang et al.,Reduction of Stromal Fibroblast-induced Mammary Tumor Growth, by Retroviral Ribozyme Transgenes to Hepatocyte Growth Factor/Scatter Factor and its Receptor, c-MET, Clin. Cancer Research (2003) , vol. 9, 4274-4281.
Kenworthy et al.,The presence of scatter factor in patients with metastatic spread to the pleura, Br. J. Cancer (1992), 66, 243-247.
Kermack et al.,Some Anilinopyridine Derivatives, J. Chem. Soc. (1942) 726.
Lai et al.,Involvement of Focal Adhesion Kinase in Hepatocyte Growth Factor-induced Scatter of Madin-Darby Canine Kidney Cells, J. Biol. Chem. (2000), vol. 275, No. 11, pp. 7474-7480.
Lee et al.,A novel germ line juxtamembrane Met mutation in human gastric cancer, Oncogene (2000) 19, 4947-4953.
Lowe et al.,Structure-Activity Relationship of Quinazolinedione Inhibitors of Calcium-Independent Phosphodiesterase, J. Med. Chem. 1991, 34, 624-628.
Lubensky et al.,Hereditary and Sporadic Papillary Renal Carcinomas with c-Met Mutations Share a Distinct Morphological Phenotype, American Journal of Pathology, vol. 155, No. 2, Aug. 1999.
Masuya et al.,The tumour-stromal interaction between intramural c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients, Br. J. of Cancer (2004) 90, 1555-1562.
Matsumoto et al.,Hepatocyte Growth Factor: Molecular Structure, Roles in Liver Regeneration, and Other Biological Functions, Crit. Review 3(1,2): 27-54 (1992).
Montesano et al.,Identification of a Fibroblast-Derived Epithelial Morphogen as Hepatocyte Growth Factor, Cell, vol. 67, 901-908, Nov. 29, 1991.
Nicolaou et al.,o-Iodoxybenzoic Acid (IBX) as a viable reagent in the manipulation of Nitrogen-and Sulfur-containing substrates; Scope, Generality, and Mechanism of IBX-Mediated Amine Oxidations and Dithiane Deprotections, J. Am. Chem. Soc. 2004, 126, 5192-5201.
Nishikawa et al.,Preparation and Structure-Activity Relationships of 4-Substituted Amino-2-methylpyrido [3,4-d] pyrimidines as Cytokinin Analogs, J. Agric. Food Chem. 1995, 43, 1034-138.
Park et al.,Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors, Proc. Natl. Acad. Sci, vol. 84, pp. 6379-6383, Sep. 1987.
Phuan et al.,Product Class 8: Naphthyridines, Science of Synthesis (2005) 15, 947-985.
Radwan et al., “Pyridazine derivatives: Synthesis and reactions of some new indeno[1,2-d]pyridazine derivatives” Pharmazie 52 (1997) 6, pp. 483-485.
Rewcastle et al.,Tyrosine Kinase Inhibitors. 10. Isometric 4-[(3-Bromophenyl)amino]pyrido[d]-pyrimidines are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor, J. Med. Chem., 1996, 39, 1823-1835.
Rogues et al., “Etudes de la bromation du furfural en presence de chlorure d'aluminium”, Bull. Soc. Chim. Fr. (1971) 1, 242-245.
Rong et al.,Met Expression and Sarcoma Tumorigenicity, Cancer Research 53, 5355-5360, Nov. 15, 1993.
Rong et al.,Met Proto-oncogene Product is Overexposed in Tumors of p53-deficient Mice and Tumors of Li-Fraumeni Patients, Cancer Research 55, 1963-1970, May 1995
Sachs et al.,Essential Role of Gab1 for Signaling by the c-Met Receptor in Vivo, J. Cell. Biol., vol. 150 (6)

Affiliated with

Also associated with

Rating

Met kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Met kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Met kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4101691